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ABSTRACT 
Background. Peritonitis and exit-site infections (ESI) are major causes of technique failure 
and morbidity in peritoneal dialysis (PD) patients. Topical mupirocin on the exit-site has been 
shown to reduce such complications and prolong life in PD. Since the year 2000, such an 
approach has been adopted for our new incident PD population. We now report the results of 
this new protocol. We also studied the effect of co-morbidity on peritonitis occurrence. 
Methods. A total of 740 incident PD patients were studied. Patients were divided into two 
groups based on year of entry into PD (Group 1 from January 1998–December 1999 without 
topical mupirocin and Group 2 from January 2000–March 2004 with topical mupirocin). 
Variables studied included gender, age, diabetic status, ischaemic heart disease, peripheral 
vascular disease, cerebrovascular disease and serum albumin. Results. Topical mupirocin at 
the exit-site has led to a significant reduction in peritonitis rate (0.443 vs 0.339 
episodes/patient-year; P<0.0005) and ESI (0.168 vs 0.156 episodes/patient-year; P<0.005) 
attributed primarily to the significant reduction in Staphylococcus aureus infections. There 
was an unexpected finding of lower Pseudomonas aeruginosa peritonitis in the mupirocin 
group (P<0.005). Stepwise multiple logistic regression analysis revealed that only mupirocin 
application and serum albumin were significant predictors of peritonitis. Conclusions. Our 
study, although limited by its retrospective nature, demonstrated that topical mupirocin was 
associated with a significant reduction in ESI and peritonitis with unexpected findings of 
lower Pseudomonas peritonitis. Serum albumin prior to the initiation of PD was a strong 
predictor of subsequent peritonitis. Mupirocin, with its low toxicity, ease of application and 
demonstrable beneficial effect in reducing ESI and peritonitis is now used on all incident PD 
patients.  
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